Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Colonic Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Squamous Cell Carcinoma of Head and Neck 1Neuropathy, Painful 1Neuralgia 1Malignant Solid Tumour 1Liver Neoplasms 1Esophageal Neoplasms 1Cold Hypersensitivity 1Carcinoma, Hepatocellular 1CRC 1Advanced Colorectal Cancer 1

Interventions

pembrolizumab 20Paclitaxel 13Fluorouracil 13Docetaxel 13Radiotherapy 12Oxaliplatin 11Cisplatin 11Capecitabine 8Carboplatin 7Leucovorin 6Cetuximab 5Nivolumab 4Albumin-Bound Paclitaxel 4atezolizumab 3Trastuzumab 3Ramucirumab 3Irinotecan 3Interleukin-2 3Injections 3Epirubicin 3Drug Therapy 3Dexamethasone 3130-nm albumin-bound paclitaxel 3tremelimumab 2tisotumab vedotin 2regorafenib 2patritumab deruxtecan 2oblimersen 2nedaplatin 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esophageal Neoplasms × Folfox protocol × Clear all
NCT03526835 2025-01-29

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Merus B.V.

Phase 1/2 Recruiting
523 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡